Abstract While there are many obstacles to immune destruction of autologous tumors, there is mounting evidence that tumor antigen recognition does occur. Unfortunately, immune recognition rarely controls clinically signiWcant tumors. Even the most eVective immune response will fail if tumors fail to express target antigens. Importantly, reduced tumor antigen expression often results from changes in gene regulation rather than irrevocable loss of genetic information. Such perturbations are often reversible by speciWc compounds or biological mediators, prompting a search for agents with improved antigen-enhancing properties. Some recent Wndings have suggested that certain conventional chemotherapeutic agents may have beneWcial properties for cancer treatment beyond their direct cytotoxicities against tumor cells. Accordingly, we screened an important subset of these agents, topoisomerase inhibitors, for their eVects on antigen levels in tumor cells. Our analyses demonstrate upregulation of antigen expression in a variety of melanoma cell lines and gliomas in response to nanomolar levels of certain speciWc topoisomerase inhibitors. To demonstrate the ability of CD8+ T cells to recognize tumors, we assayed cytokine secretion in T cells transfected with T cell receptors directed against Melan-A/ MART-1 antigen. Three days of daunorubicin treatment resulted in enhanced antigen expression by tumor cells, in turn inducing co-cultured antigen-speciWc T cells to secrete Interleukin-2 and Interferon-. These results demonstrate that speciWc topoisomerase inhibitors can augment melanoma antigen production, suggesting that a combination of chemotherapy and immunotherapy may be of potential value in the treatment of otherwise insensitive cancers.
Introduction
Immunotherapy continues to hold great promise as a clinical antitumor strategy. Yet by its nature as a process contingent upon speciWc molecular recognition events, immunological destruction of tumor cells requires the maintenance of antigenic structures on the transformed tumor targets. Thus, widespread loss of such antigens will inevitably be accompanied by immunotherapeutic failure. This logical conclusion has been supported by abundant experimental data [1, 2] . It is now recognized that the immune system itself can shape the growth of tumor populations by providing a powerful negative selection ('immunoediting') in favor of antigen-loss variants [3] . Although immune targeting against a spectrum of tumor antigens can overcome loss of individual antigens, unfortunately coordinate expression loss for an entire suite of antigens can occur if they share regulatory control mechanisms, as has been observed for many melanocyte diVerentiation antigens [4, 5] . Yet at the same time, this observation underscores a vitally important issue that we have previously demonstrated: loss of antigen expression need not arise from irreversible processes (such as gene mutation or deletion), but can (and often does) result from alterations in gene regulatory pathways [2, 6] , and such changes leave the relevant coding sequences intact, and are in principle reversible.
In response to this challenge, we have initiated screening programs for agents capable of reversing the 'antigensilencing' eVect which enables tumor escape from immune surveillance. From such studies, we have identiWed both small molecule drugs (principally kinase inhibitors; [7] ), and biological mediators (especially interferon-beta; [8] ) which actively upregulate tumor antigen expression. In order to be eVective as drugs, any such agents should show potency and appropriate pharmacokinetics in vivo. Historically, many anticancer drugs have been inherently highly toxic, and their therapeutic beneWts are founded upon the balance between maximizing their antitumor eVects and minimizing non-speciWc toxicities on bystander cells. Recent observations have added new factors to consider because some chemotherapeutic agents may have additional properties of therapeutic relevance, beyond direct tumor toxicity. For example, there are reported anti-angiogenic eVects through targeting of endothelial cells [9, 10] and beneWcial eVects on the regulatory arm of the immune system [11] [12] [13] .
Within the entire set of cytotoxic drugs used for cancer treatments, inhibitors of both topoisomerases I and II represent important and intensively studied drugs, and these compounds can also manifest anti-angiogenic or immune-enhancing eVects in suitable dosages [10, 11] . Topoisomerases are known to have roles in speciWc gene expression [14, 15] . Even more cogently, DNA damage (as induced by UV radiation or other processes) has been implicated in the activation of melanocytic genes [16] [17] [18] .
Drugs targeting topoisomerases are divided into two broad classes: the Wrst class includes most of the clinically active agents, including doxorubicin, and leads to increases in the levels of topoisomerase-DNA covalent complexes. Because these agents generate lesions that include DNA strand breaks and protein covalently bound to DNA, they have been termed topoisomerase "poisons". A second class of compounds inhibits the catalytic activity of topoisomerases, but does not generate covalent complexes. Agents in this second class are thought to kill cells through the elimination of the essential enzymatic activity of topoisomerases and are, therefore, termed "catalytic inhibitors". Both topoisomerase types I and II cause extensive genomic damage when their normal catalytic cycles are disrupted by drugs acting as poisons [19] [20] [21] .
Given these intriguing observations, we assessed whether topoisomerase inhibitors might have the added beneWt of the upregulation of tumor antigens. Therefore, we initially tested melanoma cell lines with daunorubicin (an anthracycline, in common with doxorubicin), and indeed found signiWcant antigen-enhancing eVects. Subsequent investigations showed that several topoisomerase I inhibitors can augment T cell recognition of tumor targets. These studies demonstrate the functional relationship between tumor cell antigen expression and immune function in responding T cells. The results with low-dose topoisomerase inhibitors parallel our previous Wndings with IFN-beta and MAP-kinase inhibitors, which also reconstitute T cell recognition of tumor cells otherwise escaping immune destruction [7, 8] .
Materials and methods

Cell culture, and topoisomerase inhibitors
General culture conditions for cell propagation and the origins of most of the melanoma cell lines have been previously described [2, 6] . Melanoma cells were cultured in DMEM with 10% FBS. The T cell receptor (TCR)-negative Jurkat T cell line derivative J.RT3-T3.5 was obtained from ATCC. T cells were cultured in RPMI with 10% FBS. IFNbeta-1a (Avonex) was obtained from Biogen-Idec (Cambridge, MA) and reconstituted according to the manufacturer's recommendations. The topoisomerase inhibitors daunorubicin, doxorubicin, epirubicin, etoposide, camptothecin, kaempferol, AG1387, and topotecan were purchased from CalBiochem (La Jolla, CA, USA); 10-hydroxycamptothecin, -lapachone, ellipticine, and novobiocin from BioMol (Plymouth Meeting, PA, USA); and apigenin, idarubicin, XK469, rubitecan, sobuzoxane, ATA, and Merbarone from Sigma (St. Louis, MA, USA).
EGFP reporter cell line
The generation and application of EGFP reporter cells has been previously described [8] . BrieXy, a 1,200 base pair human genomic DNA segment encompassing the Melan-A/ MART-1 promoter was used to generate a construct driving expression of the EGFP reporter gene. Stable transfectants with this construct were generated in the low-antigen cell line A375 and the high-antigen line MM96L+. The EGFP expression response patterns of these cells to IFN-beta and MAP kinase inhibitors recapitulates the antigen upregulation of endogenous Melan-A/MART-1 induced by these agents [8] .
Toxicity measurements
The toxicity of compounds was measured using the WST reagent system from Roche (Indianapolis, IN, USA) [22] . Cells were plated in a 96-well culture plate. The time zero absorbance (A 0 ) was measured at 450 nm 24 h after plating, and inhibitors were added at this time. Cells were allowed to grow for an additional 48 h. WST was added to each well and after 1 h the hydrolysis of the WST was read in a plate reader at 450 nm. Wells were normalized by subtracting a 655 nm background reading. Triplicates for each sample were determined. A control for medium only (A Con ) was subtracted from each reading.
Treatment of cells with topoisomerase inhibitors
Cells were plated at a density of 1 £ 10 5 in 1 ml of media in a 24-well plate and cultured for varying times as indicated in the "Results". Typically, 3 days of culture in the presence of topoisomerase inhibitors was optimal for the functional studies performed. After incubation, cells were collected by trypsinization and then evaluated using Xow cytometry.
Flow cytometry
Staining and Xow cytometric analyses of cytoplasmic Melan-A/MART-1 and gp100 expression were performed as described previously [6] . Cells were Wxed with 1% formaldehyde, permeabilized with 0.1% saponin, stained with monoclonal antibodies to melanocyte antigens (MART-1, Vector Labs; gp100 HMB45, DakoCytomation), and then visualized with goat anti-mouse FITC-conjugated secondary antibody (Zymed). The level of EGFP was determined by Xow cytometry of unWxed cells washed and resuspended in 1£ PBS.
Generation of TCR-encoding lentiviral particles
The previously published codon-optimized sequence (1D3 [23, 24] ) was synthesized by GeneArt (Burlingame, CA, USA) and placed into a third generation lentiviral transfer vector [25] . The TCR and TCR sequences were separated by a P2A sequence as previously described to facilitate coordinate expression under control of the EF-1 promoter [26] . Lentiviral vector containing supernatants were prepared as previously described [27] . BrieXy, the 1D3 transfer vector was co-transfected with the expression vectors encoding HIV-1 REV , HIV-1 GAG · POL , and VSV-G into 293 T cells. After 48 h, media supernatants containing the virus particles were collected and these were concentrated using a 100 KDa molecular weight cut-oV Wlter. Virus titers were determined by infecting J.RT3 cells and staining for CD3. A pool of transduced J.RT3 cells stably expressing the exogenous Melan-A/MART-1 speciWc TCR at >95% eYciency was expanded for further use.
Assays of CD8+ T lymphocytes
Primary CD8+ T lymphocytes were obtained using heparin-treated blood incubated with a negative selection cocktail RosettaSep from STEMCELL Technologies (Vancouver, BC, Canada) to generate 95% pure CD8 T cells. These cells were stimulated for 24 h with CD3/CD28 beads (Invitrogen Dynal AS, Oslo, Norway), and cultured with 200 U/ml recombinant IL-2 (Proleukin) from Cetus (Emeryville, CA, USA) supplemented media. For transduction of the Melan-A/MART-1 speciWc TCR, 1 £ 10 5 stimulated primary CD8 cells were incubated with lentiviral vector at a MOI of 10. Cells were grown for 2 days after lentiviral infection and then stained with tetramer as described below. The CD8+ T cells were further propagated for 2 weeks in medium containing 200 U/ml recombinant IL-2 prior to use in cellular assays described below.
Tetramer staining
Tetramers were prepared by assembly of denatured recombinant major histocompatibility complex (MHC) Class I HLA-A2 plus peptide followed by dialysis [28] . Cells were incubated with MHC class I tetramers conjugated to phycoerythrin (PE) (kindly provided by Pedro Romero of Ludwig Institute for Cancer Research, Lausanne) with the Melan-A/ MART-1 peptide ELAGIGILTV. Staining buVer contained 0.1% sodium azide and 0.1% BSA. Staining was carried out at room temperature. Cells were washed, stained, and then rewashed before evaluation by Xow cytometry.
Assay for T cell activation by tumor cells
Melanoma cells were treated with antigen-modulating agents (daunorubicin or IFN-) for 3 days prior to counting and plating for the co-culture assay (cells were washed and resuspended in fresh medium that no longer contained the treatment agents during the co-culture). A 100 l aliquot of 5 £ 10 5 cells/ml tumor cells was mixed with 50 l of 5 £ 10 5 cells/ml T cells in a 96-well V-bottom plate and incubated overnight (16-24 h ). Plates were centrifuged to pellet the cells and 120 l of supernatant Xuid was removed from each well for cytokine assay. To assess antigenspeciWc T cell responses, 3.33 g/ml Melan-A/MART-1 peptide was added to the co-culture. The sequence of the Melan-A/MART-1 peptide was 26 ELAGIGILTV 35 (A27L from wild type) and the NY-ESO-1 peptide was Cytokine ELISA
The protocols for evaluation of either IL-2 or IFN-were similar, following the manufacturer's recommendations. A standard curve using known concentrations of each cytokine was included in each ELISA experiment. ELISA plates were coated with capture antibody and then washed with 1£ PBS 0.5% Tween-20. Wells were blocked with 1£ PBS 1% FBS for 1 h and rewashed. Supernatants and standards were added to the wells and incubated for 2 h at room temperature and wells were washed again. The detection antibody and HRP secondary were added together and incubated for 1 h. The HRP color reaction proceeded for 15 min before being stopped with 2 N H 2 SO 4 . The absorbance 450 nm was read in a BioRad 3550 plate reader. IL-2 levels for experimental samples (pg/ml) were calculated from the standard curve.
Results
Enhanced antigen expression on melanomas and gliomas by daunorubicin
We utilized a series of melanomas and gliomas to demonstrate augmentation of antigen expression after a 3-day exposure to the anthracycline topoisomerase II inhibitor daunorubicin. Table 1 lists the resulting increases in antigen expression when cells were treated with 100 nM daunorubicin for 3 days. An example of the Xow results for antigen expression is provided in the bottom panels of Fig. 1 (further examples are provided in Supplementary Data; Fig. SD1 ). These demonstrations included enhancement of Melan-A/MART-1 on melanomas with both high (MU89, MM96L+, MO, 136.2) and low (MUX, MM96L-, A375 and H59-44T) initial antigen expression. In addition, daunorubicin augmented levels of gp100 (HMB-45) on these melanomas, and also boosted gp100 expression in two gliomas (U-87 and U-118).
Since previous work demonstrated that cellular responses to other antigen upregulating agents (IFN-beta and MAP kinase inhibitors) were recapitulated using an extended Melan-A/MART-1 promoter/EGFP reporter system [8] , we tested the same reporter cell lines with topoisomerase inhibitor assays. We accordingly showed that these cell lines produced a similar augmentation of EGFP Xuorescence in response to daunorubicin as for endogenous Melan-A/ MART-1 itself (Fig. 1) . The Melan-A/MART-1 promoter/ EGFP reporter system was then used for dose-response studies. As shown in Fig. 2 , the 100 nM dose of daunorubicin is optimal on the MU89 cell line, and similar doses are eVective on the other cell lines tested. It is noteworthy that daunorubicin was quite toxic at the 100 nM dosage (Supplementary Data; Fig. SD2 ), and at 200 nM (and above), the vast majority of cultured tumor cells cannot survive the 3-day culture period of this drug. Notably, the surviving daunorubicin-treated tumor cells undergo signiWcant size and morphological changes, becoming much larger and more irregularly shaped than controls (These cellular alterations can be quantiWed by Xow cytometry (Supplementary Data; Fig. SD2 ), by determining the increases in forward scatter (as an index of cell size), and side scatter (reXecting increased intracellular complexity and granularity).
While the initial studies were performed at 3 days of culture, two types of kinetic observations were then made, by both varying the culture period, and determining how long the daunorubicin must be present in order to be eVective. With our validated Melan-A/MART-1 promoter EGFP reporter system [8] , we showed that treated cells take more than 2 days to manifest signiWcant increases in Melan-A/ MART-1 reporter activity (Fig. 3a) , but this increase continues beyond 3 days of culture and plateaus between 4 and 6 days. The cumulative eVects of the toxicity and culture crowding conditions lead to a decrease in antigen expression at the two higher doses of daunorubicin at day 7 (Fig. 3a) . Transient high concentrations of daunorubicin (¸200 nM) induce maximal Melan-A/MART-1 promoter upregulation with short exposures (2-6 h). At these higher doses, daunorubicin toxicity limits the feasible exposure time, but cells can survive for several days if the high drug levels are removed after treatments of ·6 h duration. While it takes several days for the antigen expression to manifest in daunorubicin-treated cells, it is notable that the tumor cells need to be in the presence of the drug only for few hours to manifest antigen-enhancing activity (Fig. 3b) . At the highest doses, 500 and 1,000 nM, the level of EGFP has reached a maximum plateau at the earliest time point tested (2 h) and does not increase at 4-and 6-h time points. Thus, the highest doses of daunorubicin are already optimally active if the drug is present for as little as 2 h. It is noteworthy that because of the short exposure time, between 2 and 6 h, high doses of daunorubicin, 200, 500, and 1,000 nM, can be tolerated; longer exposure to these high doses is too toxic to allow data collection at the 3-day time point. Thus, the decreased time of exposure to higher doses reduced toxicity enough to allow cells to survive under these conditions. The lower doses of daunorubicin take a longer time to fully optimize activity, although again they are quite active in only short exposure cultures. At lower doses, 25 and 50 nM, two phases of the curve are observed: a slow increase until 12 h and then a sharper increase. In contrast, an intermediate dose (100 nM, the dose at which most assays were carried out) has a straight-line increase in EGFP levels, where the EGFP level increases with increasing time of exposure. Daunorubicin and many other topoisomerase inhibitors can intercalate into DNA duplexes and remain bound [29] [30] [31] , consistent with changes induced by high doses, even after excess drug is removed from culture. At lower doses of daunorubicin (25 and 50 nM) exposure for at least 24 h is required to induce a 2-fold increase in Melan-A/MART-1 reporter activity (Fig. 3b) .
As the functional relevance of antigen upregulation for immunotherapy is intimately linked with recognition of tumor targets by CD8+ cytotoxic T lymphocytes (CTLs), we also tested the eVect of daunorubicin on Class I MHC expression. We found that expression of MHC Class I was reproducibly elevated by daunorubicin treatment of four melanoma cell lines (Table SD1 ). Since T cell recognition of tumors depends on both nominal antigen and the presenting MHC molecule, the fact that the daunorubicin enhances expression of both of these proteins would provide an advantage to the cellular immune response against treated tumor cells. In the absence of TCR expression, the initial J.RT3 cells cannot express surface CD3 as part of the normal antigen receptor and signal transduction complex [32] . As shown in Fig. 4a , transduction of the speciWc T cell receptor allows J.RT3 cells to express both surface CD3 (Fig. 4ai) , and bind Melan-A/MART-1 peptide/HLA-A2 tetramers (Fig. 4aii) . Transduction of the same T cell receptor into primary activated CD8+ T cells also resulted in binding of the same speciWc tetramers (Fig. 4aiii ).
More importantly, as shown in Fig. 4b , when these same TCR-transduced T cells are presented with antigen, they produce readily detectable levels of speciWc cytokines. Engagement of the transduced TCRs results in production of IL-2 (shown with J.RT3 Jurkat cells; Fig. 4bi ), or IFN-(shown with primary CD8+ T cells; Fig. 4bii ). As can be readily appreciated, the J.RT3 cells in Fig. 4bi produce low levels of IL-2 in response to control HLA-A2+ MU89 cells. Daunorubicin treatment induced nearly 5-fold enhanced IL-2 production. This very signiWcant induction constituted »50% of the experimental maximum observed when all available surface HLA-A2 molecules on the target cells are artiWcially saturated through pulsing with excess speciWc Melan-A/MART-1 peptide (Fig. 4bi ). An unrelated HLA-A2-restricted peptide (NY-ESO-1) failed to induce IL-2, demonstrating the speciWcity of this antigen-recognition process.
Similarly, primary CD8+ T cells expressing the same TCRs with Melan-A/MART-1 peptide/HLA-A2 speciWcity respond to daunorubicin-treated tumor cells with production of IFN-over 4-fold the background activity seen with untreated MU89 cells. This high level of response was similar to that resulting from IFN-stimulation of MU89 cells, or these tumor cells pulsed with Melan-A/MART-1 peptide (Fig. 4bii) . Both the untransduced J.RT3 cells and the untransduced PBL produce no cytokine when confronted Fig. 3 a Kinetics of daunorubicin response for antigen expression levels. The A375 MART::EGFP reporter melanoma tumor cells were exposed to various amounts of daunorubicin for various periods of time. b EVects of transient daunorubicin treatments on Melan-A/MART-1 expression. The A375 MART::EGFP reporter cell line was exposed to various concentrations of daunorubicin for the indicated times, after which cells were provided with drug-free media. The level of EGFP was determined 72 h after daunorubicin exposure. Note the log-scale x-axis is discontinuous, as noted by breaks in the x-axis and graphs, and the Wrst data point represents the untreated control level of EGFP indicated by zero. The geometric mean of Xow histograms is plotted with the same antigen-presenting cells, further conWrming the recognition speciWcity and sensitivity of the lentiviralinfected cells expressing the speciWc TCR.
EVects of diVerent topoisomerases on Melan-A/Mart-1 expression
We tested a series of both topoisomerase I and II inhibitory compounds with diVerent reported eVects and mechanisms. The pharmacological activity of topoisomerase inhibitors has been historically grouped into the categories of poisons (compounds stabilizing otherwise transient topoisomerase-DNA covalent complexes [20, 21] ), or catalytic inhibitors that block catalysis by direct interaction with topoisomerase protein itself [33] . Figure 5 summarizes a series of Xow studies with a range of topoisomerase inhibitors (further speciWc examples shown in Supplementary Data; Fig. SD3 ). The strongest antigen enhancement activity was shown by topoisomerase poisons, irrespective of speciWcity toward topoisomerase I or II. In contrast, the catalytic inhibitors were generally impotent at enhancing antigen. However, topoisomerase poisons are varied in activity. The structurally related anthracyclines daunorubicin, doxorubicin, epirubicin, and idarubicin are all topoisomerase II inhibitors with potent antigen enhancing capacity in the nanomolar range (Fig. 5) . The non-anthracycline topoisomerase II poisons etoposide [30] and ellipticine [34] showed signiWcant activity, although requiring a full order of magnitude higher concentration of drug than the anthracycline set (Fig SD3) . Among the topoisomerase I inhibitors, the related poisons topotecan and rubitecan are highly active, and camptothecin and hydroxy-camptothecin are also very potent, while kaempferol has detectable, but far more modest activity, in common with the catalytic topoisomerase I inhibitor AG1387. Apigenin and -lapachone were essentially inactive, despite the recorded activity of -lapachone toward both topoisomerases I and II [35, 36] . . It might be thought that an increased cell volume will only magnify the net amounts of all proteins expressed per cell unit, without an essential increase in the density of proteins per unit volume. All inhibitors that enhanced antigen expression indeed caused measurable morphological changes as well, but there was no observable correlation between cell size and shape perturbations and antigen levels (Supplementary Data; Fig. SD4 ). Moreover, some drugs that induced increases in cell size and granularity did not increase speciWc antigen expression, suggesting that the enhanced antigen expression is not merely a reXection of increased cell size and complexity. Irrespective of cell size alterations, increased antigen expression is clearly dependent on protein synthesis, as demonstrated through the eVects of the inhibitor cycloheximide (Supplementary Data; Fig. SD5 ).
Discussion
Combination therapies against tumors have a higher inherent probability of success than treatments with single agents, given the need to counter a wide variety of possible resistance mechanisms. In particular, certain combination therapies for leukemias and lymphomas have resulted in very positive outcomes [37, 38] . As we have previously noted, one of the obstacles to immunotherapy is the emergence of antigen-negative escape variants, and we have sought and identiWed agents that can enhance and restore antigen expression to augment immune recognition and destruction of the tumors [7, 8] . We were also motivated to test conventional chemotherapeutic drugs for their eVects on melanoma cell antigen expression. At high prescribed doses, these drugs are designed for antitumor cytotoxicity, yet in lower doses may also have utility in metronomic therapy against neoangiogenesis [9, 10] or by useful immune modulation [11] . In practice, standard chemotherapy has had very limited eYcacy for treatment of melanoma [39] , but upregulation of antigen levels by the same drugs might provide an additional mechanism for immunemediated cancer therapy.
Several additional factors prompted us to speciWcally examine topoisomerase inhibitors for their potential eVects on tumor antigen expression. The cytotoxic mechanisms of many of the major current anticancer drugs is attributable to blockade of topoisomerase function [20, 21, 40] , which in turn can have varied eVects on gene expression [41] [42] [43] [44] . Most importantly, the association of DNA damage with Fig. 5 EVective concentration ranges of topoisomerase inhibitors for achieving doubling of Melan-A/MART-1 reporter activity ("Methods") under the same conditions. These windows of activity (black bands) cover active concentrations spanning lower limits (loss of activity by dilution), up to maximal practical levels determined by toxicity, where all are assessed under the same exposure times in culture (72 h assay). By these criteria, sets of inhibitors were grouped through similarities in their activity patterns as high, medium, or low potency; or as having no signiWcant eVect. Inhibitors are categorized according to their major target (topoisomerase I or II), and as poisons or catalytic inhibitors in each case. Adjacent sets of inhibitors in gray shading are structurally related melanocytic gene regulation [16] [17] [18] provided a potential link between topoisomerases and melanocytic tumor antigen expression, which we elected to pursue in this study.
Our evaluation of a variety of inhibitors of both Type I and II topoisomerases showed clear-cut eVects on antigen expression, but these activities showed signiWcant diVerences among the diVerent agents. Inhibition of topoisomerases is clearly associated with upregulation of antigen expression, but this eVect is clearly not simply related to inhibition of enzyme catalysis. In fact, catalytic inhibitors showed at best very modest activities, and were mostly ineVectual (Fig. 5) . On the other hand, certain topoisomerase poisons profoundly modulated antigen levels, and moreover improved the recognition of treated tumor cells by speciWc T cells (Fig. 4) .
Considering these data, it is important to keep in mind the imperfect speciWcities of topoisomerase II inhibitors. The widely used anthracycline inhibitors daunorubicin, doxorubicin, and their derivatives are generally ascribed as directed toward topoisomerase II [40, 45] , but nevertheless have been shown to also signiWcantly target topoisomerase I, at least under some circumstances [46, 47] . Yet in contrast, camptothecin appears to be remarkably selective toward topoisomerase I [20] . Based solely on the known selectivity of camptothecin and the measurable promiscuity of anthracyclines, at present we cannot exclude the possibility that the topoisomerase target relevant to melanoma antigen expression is largely or even uniquely topoisomerase I. Even so, additional evidence is necessary to conWrm the link between topoisomerase I inhibition by camptothecin and the upregulation of antigen expression.
Comparison of the general eVectiveness of topoisomerase poisons to the poor activity of catalytic inhibitors (Fig. 5) suggests that the increased antigen levels are not simply due to ablation of topoisomerase activity in itself. Irrespective of their mechanistic details, poisons of topoisomerases are deWned by their ability to convert these normal essential enzymes into agents of destruction, by inducing the accumulation of double-stranded or singlestranded DNA breaks [48, 49] . After a certain threshold of such induced genomic damage, the end result is cell death (a desirable therapeutic outcome, of course, for tumor cells). Prior to this occurring, though, the combination of cell cycle arrest and diVerential gene expression increase may result in increased cell volumes, which we typically observe by Xow analysis of anthracycline-treated cells ("Results" and Supplementary Data; Figs. SD1 and SD4). While our data show no necessary correlation between increased cell volume and antigen expression levels, the poisoning of topoisomerases appears to produce the most potent antigen responses, as opposed to direct enzymatic inhibition. The DNA damage response, which is a direct consequence of topoisomerase poisoning [50, 51] , may consequently be the central stimulus for antigen upregulation [16] [17] [18] , rather than topoisomerase inhibition per se. Such a proposal is consistent with our results, but further work will be required to dissect the components of the topoisomerase-induced DNA damage pathway directly impinging on antigen expression.
Importantly, the ability of antigen-speciWc T cells to recognize the treated tumor cells provides a functional correlate with enhanced protein expression. Of note, our results indicate that genes for both diVerentiation antigens and MHC Class I are included among those upregulated by speciWc inhibitors directed against either topoisomerases I or II. Since both antigen and MHC are enhanced, T cell recognition of the tumors beneWts from the increase of both of these elements needed for TCR engagement of tumor cells [52] . Increased T cell activation following topoisomerase inhibitor treatment of target cells is a good correlate of improved T cell recognition of target, and in turn improved antigen presentation. Therefore, our T cell system provides a biologically meaningful read-out for the success of antigen upregulation, and in a therapeutic context, it is the most relevant in vitro assay we have available. This system unequivocally reports that the tumor antigen augmentation mediated by speciWc topoisomerase inhibitors allows greatly improved T cell recognition of melanoma targets, of crucial importance for immunotherapy.
It is becoming increasingly clear that the outcome of chemotherapy is inXuenced by critical factors beyond the direct killing of target tumor cells, including the control of angiogenesis and the successful deployment of the host immune system. Accordingly, chemotherapy and immunotherapy should not be considered in isolation from each other [53] . The importance of these observations is emphasized by remarkable recent Wndings concerning the unanticipated and therapeutically relevant eVects (beyond direct cytotoxicity) of many common chemotherapeutic agents. In suitable dose ranges, anthracyclines and other drugs have thus been shown to block angiogenesis [9, 10] , suppress Treg-mediated immune down-modulation [11, 12] , increase the eYciency of immune killing of both target and bystander tumor cells [54] , improve antigen-presentation by dendritic cells [55] , and stimulate the anticancer immune response [56, 57] .
Here, we add an additional dimension to this diverse therapeutic picture, where these agents can also potentially boost speciWc immune recognition of tumor targets and help marshal the host immune system toward antitumor cytolysis. In terms of the choice of drug doses for eVective responses, our own experience with the T cell assay suggests that high concentrations of anthracyclines can block T cell activation despite concomitant tumor antigen upregulation (unpublished observations). This Wnding is consistent with the known lymphocytic toxicity of high doses of anthracycline drugs [58] . A reduced dose in vivo which preserves antigen upregulation without ablating the eVector arm of T cell immunity is therefore highly desirable, although simultaneous dampening of the regulatory T cell arm [11] [12] [13] would be a welcomed side-beneWt.
Indeed, the potential role of antitumor immune responses in contributing to the overall success of chemotherapy in general has become a topic of recent interest [53, 59] . It is also a reasonable prospect that immunological or anti-angiogenic suppression of tumor cells surviving a primary chemical cytotoxic challenge would signiWcantly forestall the development of drug resistance in residual tumor populations. Any combination therapy against multiple independent targets in a pathogen or tumor can reduce the frequency of selection for resistant variants, since the probability of the occurrence of multiple genetic resistance mutations is accordingly lower than that for mutations countering any single agent in isolation. Treatment with appropriate topoisomerase inhibitors combined with immunotherapy therefore has the potential for a greater initial impact, since pre-existing cells which are independently either drug-resistant or low expressors of antigen are still susceptible to the combined therapeutic challenge. Following the Wrst round of treatment, survivors with druginduced antigen augmentation are then enhanced targets for ongoing immunotherapy.
An important factor determining the future utility of topoisomerase poisoning in tumor antigen modulation is the achievable levels of circulating drugs in human cancer patients, for which numerous and long-standing pharmacokinetic studies can be resourced. In the case of anthracyclines, while many diVerent dosage regimens have been used for cancer therapy, the most conservative approach is to consider the pharmacokinetic outcome of single-dose treatments. Studies with doxorubicin (the antigen upregulation eVects of which were comparable to the closely related daunorubicin; Fig. 5 ) using single treatments of 50-60 mg m ¡2 have shown patient plasma levels in the 100 nM range after 6 h, persisting to at least 30 nM after 24 h [60, 61] . These doses are well above those required in vitro for prolonged antigen upregulation (Fig. 3) , even if the drug treatments were to be immediately discontinued.
Even so, beneWcial immune responses in patients might be signiWcantly blunted, or even ablated, if the chemotherapeutic treatment proved toxic to sensitive immune eVector cells. The conundrum of drugs useful for antitumor activity, but with concurrent negative eVects on the immune system has been recently highlighted [53, 59, 62] . A powerful way to side-step this is adoptive immunotherapy, where TCRs against antigens known to be upregulated by initial treatments are transduced in vitro into autologous CD8+ T cells from patient PBLs (such as the CD8+ T cells that express TCRs speciWc for Melan-A/MART-1 used in our investigations), expanded, and re-infused back into the autologous recipient [63] after the primary chemotherapeutic treatment.
Design of a truly optimal oncological treatment regimen with designated topoisomerase inhibitors must investigate in vivo pharmacokinetics and dose responses for multiple biological eVects: direct tumor cytotoxicity, endothelial cell cytotoxicity, antigen stimulation on tumor cells, compatibility with the T cell eVector arm, and suppression of Treg cells. While a single drug may be unlikely to satisfy all these criteria, the cost-eVectiveness of repositioning existing drugs in new roles has a high current proWle in the pharmaceutical industry [64] . Our data support the contention that conventional cytotoxic topoisomerase inhibitors may Wnd new applications in therapies for melanomas and possibly other tumors.
